Guest guest Posted September 30, 2006 Report Share Posted September 30, 2006 I only know what's below. Adam: Xanthus' Symadex Remyelination Xanthus' Symadex Can Reverse Disease in Preclinical Multiple ... Yahoo! News (press release) - USA .... company, today presented data that Symadex reverses the ... Alfred Ajami, PhD, Chief Scientific Officer at Xanthus. Symadex (formerly C-1311) is the lead ... See all stories on this topic http://biz.yahoo.com/prnews/060928/neth010.html?.v=70 Press Release Source: Xanthus Pharmaceuticals, Inc. Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model Thursday September 28, 9:30 am ET - Results Presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis - CAMBRIDGE, Mass., Sept. 28 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held drug development company, today presented data that Symadex reverses the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis (MS). The presentation was made by J. Karlik, PhD, Professor of Diagnostic Radiology at the University of Western Ontario, London, Ontario, together with researchers from Xanthus in a poster session at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Madrid, Spain. Dr. Karlik used a model of experimental allergic encephalomyelitis (EAE) for the study. This same model was used by Dr. Karlik and his colleagues for published studies with natalizumab and related molecules. The study demonstrated that Symadex can reverse the clinical and pathological signs of chronic disease and that it can permit nerve remyelination. In addition, longer dosing resulted in continued benefit and the pathological changes including inflammation and vascular abnormalities were reversed. Importantly, Symadex did not affect circulating immune cell numbers, suggesting that it is not a general immunosuppressive agent. " We believe that Symadex has a distinct activity profile in the field of MS therapies. Interestingly, we found that Symadex has no effect on the acute, T-cell mediated portion of the disease process which is the target of most proposed new therapies for MS, " stated Alfred Ajami, PhD, Chief Scientific Officer at Xanthus. About Symadex Symadex (formerly C-1311) is the lead compound in clinical development from a new series of agents, the imidazoacridinones, which have shown in vitro to be potent and selective FLT3 receptor tyrosine kinase inhibitors. Symadex is currently in Phase 2 clinical trials in oncology indications. Xanthus is also exploring the use of Symadex for the treatment of a number of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, where early preclinical data has shown encouraging signs of activity. About Xanthus Pharmaceuticals, Inc. Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology. Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com. This press release contains forward-looking statements concerning Xanthus that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, " believes, " " anticipates, " " plans, " " expects, " " estimates, " " intends, " " should, " " could, " " will, " " may, " and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Xanthus' actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether results obtained in early clinical studies or in preclinical studies such as the studies referred to above will be indicative of results obtained in future clinical trials or warrant additional trials; whether products based on Xanthus' technology will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the company will have the cash resources to develop and commercialize its products; and whether the patent and patent applications owned or licensed by Xanthus will protect the Company's technology and prevent others from infringing it. Xanthus disclaims any intention or obligation to update any forward-looking statements. Contacts: Kari , MacDougall Biomedical Communications, Inc. -- kwatson@... or Terry, Xanthus Pharmaceuticals, Inc. -- lisa.terry@... or (617) 225-0522, x 105 Source: Xanthus Pharmaceuticals, Inc. Tysabri Drug Holds Promise for MS Sufferers KSL-TV - Salt Lake City,UT,USA In trials, participants who took the drug, called Tysabri, with another drug, experienced a 54% reduction in the rate of clinical relapses. ... Market Report -- Short Stories (BIIB) MSN Money - USA Target $50. Credit Suisse initiates BIIB with a Neutral and a $50 tgt saying long-term Tysabri sales difficult to predict. The firm ... Market Report -- In Play (BIIB) MSN Money - USA Biogen Idec announces new data on Tysabri demonstrate significant improvement in cognitive function in patients with multiple sclerosis Co and and Elan Corp ... Elan buys into new Alzheimer treatment Unison.ie - Bray,Ireland Elan, which is the manufacturer of the Tysabri multiple sclerosis treatment, is to link up with Toronto-based Transition Therapeutics, for the joint ... See all stories on this topic Biogen, Elan Unveil New Tysabri Data Houston Chronicle - United States and Elan Corp. said Thursday data from a late-stage study of Tysabri showed it was effective in reducing cognitive degeneration in multiple sclerosis patients. ... See all stories on this topic Say farewell to Click Commerce MSN Money - USA .... Elan (ELN, news, msgs) has been treading water since getting Tysabri re-approved in the US and Europe. In October, when the company ... Rituximab Multiple Sclerosis Rituxan is effective in relapsing-remitting multiple sclerosis Xagena.it - Italy A Phase II study of Rituximab ( Rituxan ) for relapsing-remitting multiple sclerosis ( RRMS ) met its primary endpoint. The study ... Fingolimod European Commodity Stocks May Rise as Oil and Copper Advances Bloomberg - USA .... disease. Novartis said its experimental multiple sclerosis drug, fingolimod, held the disease at bay for two years in a clinical trial. ... FREEDOMS Phase III Multiple Sclerosis New Data for FTY720 -- Aiming to Become the First Orally Effective ... Yahoo! News (press release) - USA .... This includes a Phase III clinical trials program called FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis). ... Fampridine Acorda stock jumps on promising drug trial data Reuters - USA .... The drug, Fampridine-SR, is designed to improve walking speed in patients with multiple sclerosis, a degenerative disease of the nervous system that can lead ... Market Report -- In Play (ACOR) MSN Money - USA Acorda Therapeutics announces positive results of Phase 3 Study of Fampridine-SR on walking in people with multiple sclerosis Co announces positive results ... Acorda Shares Triple on MS Drug Data MSN Money - USA .... The company released results from its Phase III study of Fampridine-SR showing that nearly 35 percent of patients taking the drug improved their walking speed ... Acorda says MS drug improves walking United Press International - USA 25 (UPI) -- US firm Acorda Therapeutics said Monday it has seen positive results from a phase 3 study of Fampridine-SR for multiple sclerosis. ... Study: Drug helps MS patients walk Newsday - Long Island,NY,USA .... sclerosis is an autoimmune disease that affects the central nervous system.Krupp said she first heard about the substance, now called Fampridine-SR, more than ... See all stories on this topic Acorda Announces Positive Phase 3 Fampridine-SR Study In People ... Medical News Today (press release) - UK (Nasdaq: ACOR) today announced positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis (MS). ... See all stories on this topic Acorda Drug Helps MS Patients in Walking; Shares Soar (Update5) Bloomberg - USA .... rose almost fourfold after the company said its experimental Fampridine drug helped people with multiple sclerosis walk faster. ... Giant Step for MS Drug Smartmoney.com - USA The big bounce comes after Acorda's Fampridine-SR drug proved in Phase III testing to help MS sufferers who'd already lost some walking ability to the ... Fampridine-SR Improves Walking Ability in MS Patients Genetic Engineering News (press release) - New Rochelle,NY,USA Acorda Therapeutics reported positive results from its Phase III trial of Fampridine-SR on walking in people with multiple sclerosis (MS). ... Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.